Inactive Instrument

Standard BioTools Inc.

Equities

SLGC

US83444K1051

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P Global BMI Index CI
Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P TMI Index CI
Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023 CI
Declaration of Voting Results by SomaLogic Inc CI
Declaration of Voting Results by SomaLogic Inc CI
Declaration of Voting Results by SomaLogic Inc CI
Declaration of Voting Results by SomaLogic Inc CI
Declaration of Voting Results by SomaLogic Inc CI
Standard BioTools Says Merger With SomaLogic Completed MT
SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger MT
SomaLogic, Inc.(NasdaqGM:SLGC) dropped from NASDAQ Composite Index CI
Madryn Asset Addresses SomaLogic?s Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools CI
Madryn Asset Management, LP Sends an Email to Stockholders in Connection with Somalogic, Inc.?s Special Meeting of Stockholders CI
Madryn Asset Management Sent a Letter to the Delaware Court of Chancery CI
Madryn Asset Provides Information to the Shareholders CI
Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc CI
SomaLogic Sends an Open Letter to Shareholders CI
SomaLogic Sends an Open Letter to Shareholders CI
SomaLogic Sends an Open Letter to Shareholders CI
SomaLogic Sends an Open Letter to Shareholders CI
Chart Standard BioTools Inc.
More charts
SomaLogic, Inc. is a commercial-stage proteomics company. The Company has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. It offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Standard BioTools Inc. - Nasdaq
  4. News Standard BioTools Inc.
  5. Earnings Flash (SLGC) SOMALOGIC Posts Q1 Loss $-0.02, vs. Street Est of $-0.14